Abstract
The aim of this study was to examine the protective action of (±)-(E)-ethyl-2-[(E)-hydroxyimino-5-nitro-3-hexenamide (FK409), a novel spontaneous nitric oxide releaser, on gastric lesions in experimental rats in comparison with cimetidine, the most popular histamine H2 antagonist. Both FK409 and cimetidine, administered orally, inhibited gastric lesion, induced by water immersion stress, dose-dependently, and their inhibitions were significant at 3.2 and 32 mg kg−1 respectively. However, only FK409 (32 mg kg−1, p.o.) significantly inhibited gastric lesion induced by acidified aspirin (76%). Cimetidine (up to 100 mg kg−1, p.o.) showed only 36% inhibition. FK409 has more potent anti-ulcer activity than cimetidine and in particular shows superior gastric cytoprotection in acidified aspirin-induced lesions. Thus, FK409 could become a beneficial orally active anti-ulcer drug for clinical use.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
